{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:10:52Z","timestamp":1777029052596,"version":"3.51.4"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.pharmthera.2015.05.010","type":"journal-article","created":{"date-parts":[[2015,5,16]],"date-time":"2015-05-16T05:07:35Z","timestamp":1431752855000},"page":"10-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Pharmacotherapy for alcohol dependence: A stratified approach"],"prefix":"10.1016","volume":"153","author":[{"given":"A.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.P.","family":"Pushpakom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Faizal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pirmohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2015.05.010_bb0005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.alcohol.2009.09.031","article-title":"Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives","volume":"43","author":"Addolorato","year":"2009","journal-title":"Alcohol"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","article-title":"Dose\u2013response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Addolorato","year":"2011","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0015","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008537.pub2","article-title":"Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome","volume":"6","author":"Amato","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005063.pub3","article-title":"Benzodiazepines for alcohol withdrawal","volume":"3","author":"Amato","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0030","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","article-title":"An evaluation of \u03bc-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study","volume":"65","author":"Anton","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0040","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.jcp.0000130555.63254.73","article-title":"A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence","volume":"24","author":"Anton","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0045","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/j.1530-0277.2012.01807.x","article-title":"Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes","volume":"36","author":"Anton","year":"2012","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0050","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1530-0277.2008.00735.x","article-title":"Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers","volume":"32","author":"Arias","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1521-0391.2014.12102.x","article-title":"Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans","volume":"23","author":"Arias","year":"2014","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pbb.2012.08.019","article-title":"Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol","volume":"103","author":"Ashenhurst","year":"2012","journal-title":"Pharmacology, Biochemistry, and Behaviour"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0065","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1001\/archpsyc.1992.01820080007002","article-title":"Types of alcoholics, I: evidence for an empirically derived typology based on indicators of vulnerability and severity","volume":"49","author":"Babor","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0070","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","article-title":"Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?","volume":"30","author":"Bart","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1017\/S1461145712000375","article-title":"Genome-wide gene-set analysis for identification of pathways associated with alcohol dependence","volume":"16","author":"Biernacka","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0080","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","article-title":"A meta-analysis of topiramate's effects for individuals with alcohol use disorders","volume":"38","author":"Blodgett","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1530-0277.2008.00804.x","article-title":"Effects of alcoholism typology on response to naltrexone in the COMBINE study","volume":"33","author":"Bogenschutz","year":"2009","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0090","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1360-0443.2004.00763.x","article-title":"Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review","volume":"99","author":"Bouza","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0095","doi-asserted-by":"crossref","first-page":"g2017","DOI":"10.1136\/bmj.g2017","article-title":"Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency","volume":"348","author":"Braillon","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1369-1600.2012.00442.x","article-title":"Association of \u03bc\u2010opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta\u2010analysis","volume":"17","author":"Chamorro","year":"2012","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0105","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0006-8993(91)90050-6","article-title":"Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens","volume":"543","author":"Chen","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00002018-199920050-00003","article-title":"Safety issues concerning the use of disulfiram in treating alcohol dependence","volume":"20","author":"Chick","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0115","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/alcalc\/35.2.176","article-title":"United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol","volume":"35","author":"Chick","year":"2000","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0120","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archpsyc.1981.01780330019001","article-title":"Inheritance of alcohol abuse: cross-fostering analysis of adopted men","volume":"38","author":"Cloninger","year":"1981","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0125","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/FPC.0b013e32834c5445","article-title":"OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence","volume":"21","author":"Coller","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0130","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.addbeh.2012.12.018","article-title":"A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil","volume":"38","author":"Correa Filho","year":"2013","journal-title":"Addict. Behav."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0135","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/ijo.2010.276","article-title":"Opiates, overeating and obesity: a psychogenetic analysis","volume":"35","author":"Davis","year":"2011","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2012.00103","article-title":"Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients","volume":"3","author":"De Beaurepaire","year":"2012","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1940-0640-8-12","article-title":"Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration","volume":"8","author":"Del Re","year":"2013","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0150","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0272989X14537558","article-title":"A Bayesian mixed treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials","volume":"34","author":"DeSantis","year":"2014","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0155","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/j.1530-0277.2007.00470.x","article-title":"Family\u2010based association analyses of alcohol dependence phenotypes across DRD2 and neighboring gene ANKK1","volume":"31","author":"Dick","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0160","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/01.ALC.0000139704.88862.01","article-title":"Effects of naltrexone and nalmefene on subjective response to alcohol among non\u2010treatment\u2010seeking alcoholics and social drinkers","volume":"28","author":"Drobes","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0165","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/01.ALC.0000130974.50563.04","article-title":"Treatment outcomes in type A and B alcohol dependence 6months after serotonergic pharmacotherapy","volume":"28","author":"Dundon","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0170","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1530-0277.2010.01156.x","article-title":"Genome\u2010wide association study of alcohol dependence implicates a region on chromosome 11","volume":"34","author":"Edenberg","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0175","first-page":"22","article-title":"ALDH2, ADH1B, and ADH1C genotypes in Asians: a literature review","volume":"30","author":"Eng","year":"2007","journal-title":"Alcohol Research & Health"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11920-013-0412-1","article-title":"Genetic influences on the development of alcoholism","volume":"15","author":"Enoch","year":"2013","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0185","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1126\/science.332.6030.653","article-title":"Addiction research. Anonymous alcoholic bankrolls trial of controversial therapy","volume":"332","author":"Enserink","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0190","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/01.ALC.0000141640.48924.14","article-title":"Baclofen for alcohol dependence: a preliminary open\u2010label study","volume":"28","author":"Flannery","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1360-0443.2004.00597.x","article-title":"Does disulfiram have a role in alcoholism treatment today?","volume":"99","author":"Fuller","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0200","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2174\/138161210791516459","article-title":"Efficacy and tolerability of naltrexone in the management of alcohol dependence","volume":"16","author":"Garbutt","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0205","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/add.12557","article-title":"Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence","volume":"109","author":"Garbutt","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0210","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0215","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1530-0277.2007.00339.x","article-title":"Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA cooperative study","volume":"31","author":"Gelernter","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0220","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/mp.2013.145","article-title":"Genome-wide association study of alcohol dependence: significant findings in African- and European-Americans including novel risk loci","volume":"19","author":"Gelernter","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0225","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"Gual","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0230","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/mp.2012.179","article-title":"Opioid receptor mu 1 gene, fat intake and obesity in adolescence","volume":"19","author":"Haghighi","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0235","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ajhg.2013.10.021","article-title":"Integrating GWASs and human protein interaction networks identifies a gene subnetwork underlying alcohol dependence","volume":"93","author":"Han","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0240","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1530-0277.1996.tb01080.x","article-title":"Alcohol and aldehyde dehydrogenase genotypes and drinking behavior in Japanese","volume":"20","author":"Higuchi","year":"1996","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0245","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2165\/00023210-200418150-00005","article-title":"Role of the serotonergic system in the neurobiology of alcoholism","volume":"18","author":"Johnson","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0250","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2174\/138161210791516404","article-title":"Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients","volume":"16","author":"Johnson","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0255","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archpsyc.61.9.905","article-title":"Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial","volume":"61","author":"Johnson","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0260","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: a randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0265","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","article-title":"Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking","volume":"168","author":"Johnson","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0270","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00213-002-1002-9","article-title":"Ondansetron reduces the craving of biologically predisposed alcoholics","volume":"160","author":"Johnson","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0275","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","article-title":"Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial","volume":"284","author":"Johnson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0285","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0280","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/archinte.168.11.1188","article-title":"Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial","volume":"168","author":"Johnson","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0290","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1176\/appi.ajp.2013.12091163","article-title":"Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron","volume":"170","author":"Johnson","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0295","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2217\/pgs.14.121","article-title":"Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis","volume":"15","author":"Jonas","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0300","series-title":"Alcohol-attributable fractions for England: alcohol-attributable mortality and hospital admissions","author":"Jones","year":"2008"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0305","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.biopsych.2013.10.020","article-title":"Genetic variation in the atrial natriuretic peptide transcription factor GATA4 modulates amygdala responsiveness in alcohol dependence","volume":"75","author":"Jorde","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0310","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.drugalcdep.2014.05.023","article-title":"Genome-wide survival analysis of age at onset of alcohol dependence in extended high-risk COGA families","volume":"142","author":"Kapoor","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0315","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1530-0277.2007.00401.x","article-title":"Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double\u2010blind placebo\u2010controlled multicenter study","volume":"31","author":"Karhuvaara","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0320","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.103","article-title":"Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate","volume":"4","author":"Karpyak","year":"2014","journal-title":"Translational psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0325","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1001\/jama.1992.03490140085040","article-title":"A population-based twin study of alcoholism in women","volume":"268","author":"Kendler","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0330","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1530-0277.2010.01427.x","article-title":"Genomewide association analysis of symptoms of alcohol dependence in the molecular genetics of schizophrenia (MGS2) control sample","volume":"35","author":"Kendler","year":"2011","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0335","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/archpsyc.1997.01830140090015","article-title":"Temperance board registration for alcohol abuse in a national sample of Swedish male twins, born 1902 to 1949","volume":"54","author":"Kendler","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0340","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1037\/h0080151","article-title":"The epidemiology of co\u2010occurring addictive and mental disorders: implications for prevention and service utilization","volume":"66","author":"Kessler","year":"1996","journal-title":"Am. J. Orthopsychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0345","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000083037","article-title":"Pharmacological relapse prevention of alcoholism: clinical predictors of outcome","volume":"11","author":"Kiefer","year":"2005","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0350","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1369-1600.2007.00073.x","article-title":"Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone","volume":"13","author":"Kiefer","year":"2008","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0355","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1369-1600.2004.tb00534.x","article-title":"Neuroendocrine pathways of addictive behaviour","volume":"9","author":"Kiefer","year":"2004","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0360","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/tpj.2010.51","article-title":"Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate","volume":"11","author":"Kiefer","year":"2011","journal-title":"The Pharmacogenomics Journal"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0370","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00213-008-1330-5","article-title":"A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients","volume":"201","author":"Kim","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0365","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1111\/acer.12482","article-title":"Association between HTR7 genetic polymorphisms and alcohol dependence, using the alcohol use disorders identification test (AUDIT)","volume":"38","author":"Kim","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0375","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.2174\/0929867033456459","article-title":"Natriuretic peptides in alcohol withdrawal: central and peripheral mechanisms","volume":"10","author":"Kovacs","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0380","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1369-1600.2012.00471.x","article-title":"Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment","volume":"18","author":"Kranzler","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0385","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1017\/S1461145714000510","article-title":"GRIK1 Genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink","volume":"17","author":"Kranzler","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0390","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/JCP.0b013e31820465fa","article-title":"A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype","volume":"31","author":"Kranzler","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0395","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","article-title":"Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism","volume":"171","author":"Kranzler","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0400","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1530-0277.2011.01609.x","article-title":"Comparison of alcoholism subtypes as moderators of the response to sertraline treatment","volume":"36","author":"Kranzler","year":"2012","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0405","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/01.ALC.0000075547.77464.76","article-title":"Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study","volume":"27","author":"Kranzler","year":"2003","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0410","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.addbeh.2011.12.010","article-title":"Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection","volume":"37","author":"Leggio","year":"2012","journal-title":"Addict. Behav."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0415","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11065-008-9080-z","article-title":"Typologies of alcohol dependence. From Jellinek to genetics and beyond","volume":"19","author":"Leggio","year":"2009","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0420","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.psyneuen.2011.02.010","article-title":"The TTTAn aromatase (CYP19A1) polymorphism is associated with compulsive craving of male patients during alcohol withdrawal","volume":"36","author":"Lenz","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0425","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF02255976","article-title":"The European acamprosate trials: conclusions for research and therapy","volume":"8","author":"Lesch","year":"2001","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0430","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/oxfordjournals.alcalc.a008221","article-title":"Subtypes of alcoholism and their role in therapy","volume":"31","author":"Lesch","year":"1996","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0435","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2515\/therapie\/2014038","article-title":"Efficacy of baclofen on abstinence and craving in alcohol-dependent patients: a meta-analysis of randomized controlled trials","volume":"69","author":"Lesouef","year":"2014","journal-title":"Therapie"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0440","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3760\/cma.j.issn.0366-6999.20132647","article-title":"Genome-wide association study knowledge-driven pathway analysis of alcohol dependence implicates the calcium signaling pathway","volume":"127","author":"Li","year":"2014","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0445","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1369-1600.2012.00454.x","article-title":"Medications development to treat alcohol dependence: a vision for the next decade","volume":"17","author":"Litten","year":"2012","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0450","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta\u2010analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0455","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0460","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1530-0277.2008.00884.x","article-title":"Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study","volume":"33","author":"Mann","year":"2009","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0465","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1530-0277.2008.00690.x","article-title":"Acamprosate: recent findings and future research directions","volume":"32","author":"Mann","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0470","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/adb.12012","article-title":"Results of a double\u2010blind, placebo\u2010controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study","volume":"18","author":"Mann","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0475","first-page":"209","article-title":"The epidemiology of alcoholic liver disease","volume":"27","author":"Mann","year":"2003","journal-title":"Alcohol Research & Health"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0480","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.drugalcdep.2008.07.018","article-title":"Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty","volume":"99","author":"Mark","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0485","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/clpt.2011.355","article-title":"Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing","volume":"91","author":"Martin","year":"2012","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0490","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1530-0277.2011.01616.x","article-title":"Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data","volume":"36","author":"Mason","year":"2012","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0495","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","article-title":"A double\u2010blind, placebo\u2010controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCI for alcohol dependence","volume":"18","author":"Mason","year":"1994","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0500","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"Mason","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0505","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1139\/y01-037","article-title":"Regulation of the ANF and BNP promoters by GATA factors: lessons learned for cardiac transcription","volume":"79","author":"McBride","year":"2001","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0510","doi-asserted-by":"crossref","first-page":"g2012","DOI":"10.1136\/bmj.g2012","article-title":"Bad medicine: using surrogate markers","volume":"348","author":"McNulty","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0515","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/archgenpsychiatry.2009.55","article-title":"Predictive value of family history on severity of illness: the case for depression, anxiety, alcohol dependence, and drug dependence","volume":"66","author":"Milne","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0520","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005064.pub3","article-title":"Anticonvulsants for alcohol withdrawal","volume":"3","author":"Minozzi","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0525","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1530-0277.2007.00592.x","article-title":"Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study","volume":"32","author":"Miranda","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0530","series-title":"Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety","author":"Morley","year":"2014"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0535","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cct.2013.08.002","article-title":"The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial","volume":"36","author":"Morley","year":"2013","journal-title":"Contemporary Clinical Trials"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0540","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/humu.20039","article-title":"Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23. 1","volume":"23","author":"Neville","year":"2004","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0545","article-title":"Diagnosis, assessment and management of harmful drinking and alcohol dependence","volume":"115","author":"NICE","year":"2009"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0550","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1530-0277.2008.00682.x","article-title":"Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non\u2010natives residing in rural settings: a randomized controlled trial","volume":"32","author":"O'Malley","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0555","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1345\/aph.1L157","article-title":"Topiramate for alcohol dependence","volume":"42","author":"Olmsted","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0560","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1369-1600.2009.00159.x","article-title":"Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators","volume":"14","author":"Ooteman","year":"2009","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0565","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/sj.npp.1300219","article-title":"A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients","volume":"28","author":"Oslin","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0570","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jamapsychiatry.2014.3053","article-title":"Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial","volume":"75","author":"Oslin","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0575","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00439-013-1281-8","article-title":"Extended genetic effects of ADH cluster genes on the risk of alcohol dependence: from GWAS to replication","volume":"132","author":"Park","year":"2013","journal-title":"Hum. Genet."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0580","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/10550490490459906","article-title":"Gender differences in response to sertraline pharmacotherapy in type A alcohol dependence","volume":"13","author":"Pettinati","year":"2004","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0585","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1530-0277.2000.tb04648.x","article-title":"Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype","volume":"24","author":"Pettinati","year":"2000","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0590","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00004714-200104000-00005","article-title":"Double-blind clinical trial of sertraline treatment for alcohol dependence","volume":"21","author":"Pettinati","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0595","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.drudis.2011.08.006","article-title":"Pharmacogenetics: past, present and future","volume":"16","author":"Pirmohamed","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0600","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMoa1311386","article-title":"A randomized trial of genotype-guided dosing of warfarin","volume":"369","author":"Pirmohamed","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0605","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1176\/ajp.156.1.34","article-title":"Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins","volume":"156","author":"Prescott","year":"1999","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0610","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/187152710790966704","article-title":"Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics","volume":"9","author":"Ray","year":"2010","journal-title":"CNS & Neurological Disorders Drug Targets"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0615","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0620","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/tpj.2011.10","article-title":"Pathway based analysis of genotypes in relation to alcohol dependence","volume":"12","author":"Reimers","year":"2011","journal-title":"The Pharmacogenomics Journal"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0625","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1749-6632.2012.06794.x","article-title":"The genetics of alcohol dependence","volume":"1282","author":"Rietschel","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0630","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0006-8993(96)00068-6","article-title":"[3H]naloxone binding in the human brain: alcoholism and the TaqI A D2 dopamine receptor polymorphism","volume":"718","author":"Ritchie","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0635","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1530-0277.2012.01781.x","article-title":"Commentary on comparison of alcoholism subtypes as moderators of the response to sertraline treatment","volume":"36","author":"Roache","year":"2012","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0640","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/j.1530-0277.2008.00717.x","article-title":"Prediction of serotonergic treatment efficacy using age of onset and type A\/B typologies of alcoholism","volume":"32","author":"Roache","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0645","article-title":"Acamprosate for alcohol dependence","author":"Rosner","year":"2010","journal-title":"Cochrane Database Syst. Rev"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb9000","article-title":"Polymorphism for m-opioid receptor (+118) as a prognostic variable of naltrexone in alcohol dependence treatment: preliminary results","volume":"12","author":"Rubio","year":"2002","journal-title":"Eur Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0650","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/alcalc\/agh151","article-title":"Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone?","volume":"40","author":"Rubio","year":"2005","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0655","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/npp.2012.195","article-title":"Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues","volume":"38","author":"Schacht","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0660","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1527-3458.2008.00041.x","article-title":"Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate","volume":"14","author":"Shank","year":"2008","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0665","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.drugalcdep.2010.06.011","article-title":"Effect of the threat of a disulfiram\u2013ethanol reaction on cue reactivity in alcoholics","volume":"112","author":"Skinner","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","author":"Skinner","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0675","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0680","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1017\/S1461145713001284","article-title":"Nalmefene for the treatment of alcohol dependence: a current update","volume":"17","author":"Soyka","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0685","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/npp.2013.264","article-title":"Acamprosate produces its anti-relapse effects via calcium","volume":"39","author":"Spanagel","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0690","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1531","article-title":"Bad medicine: nalmefene in alcohol misuse","volume":"348","author":"Spence","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0695","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S1461145704004997","article-title":"Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials","volume":"8","author":"Srisurapanont","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0700","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.tins.2009.08.001","article-title":"BK channels: mediators and models for alcohol tolerance","volume":"32","author":"Treistman","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0705","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archgenpsychiatry.2009.83","article-title":"Genome-wide association study of alcohol dependence","volume":"66","author":"Treutlein","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0710","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd2251","article-title":"Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers","volume":"6","author":"Trusheim","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0715","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev.med.49.1.173","article-title":"The role of glutamatergic neurotransmission in the pathophysiology of alcoholism","volume":"49","author":"Tsai","year":"1998","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0720","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","article-title":"Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies","volume":"48","author":"van den Brink","year":"2013","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0725","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881114527362","article-title":"Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study","volume":"28","author":"van den Brink","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0730","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00213-004-1991-7","article-title":"Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients","volume":"178","author":"Verheul","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0735","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/nm0910-969","article-title":"Cocaine sobers up","volume":"16","author":"Weinshenker","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0740","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1528-1157.2000.tb02165.x","article-title":"Topiramate modulates GABA\u2010evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism","volume":"41","author":"White","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0745","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF01970149","article-title":"Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses","volume":"12","author":"Wuis","year":"1990","journal-title":"Pharmaceutisch Weekblad"},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0750","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm.2200","article-title":"Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis","volume":"16","author":"Yao","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0755","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/acer.12278","article-title":"Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial","volume":"38","author":"Yoshimura","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pharmthera.2015.05.010_bb0760","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ajmg.b.31136","article-title":"Genome\u2010wide association study of theta band event\u2010related oscillations identifies serotonin receptor gene HTR7 influencing risk of alcohol dependence","volume":"156","author":"Zlojutro","year":"2011","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815001011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815001011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T01:27:58Z","timestamp":1717896478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725815001011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":153,"alternative-id":["S0163725815001011"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.05.010","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy for alcohol dependence: A stratified approach","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}